Vertex Pharmaceuticals Incorporated (VRTX) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Vertex Pharmaceuticals Incorporated (VRTX) Bundle
Designed for accuracy, our (VRTX) DCF Calculator enables you to evaluate Vertex Pharmaceuticals Incorporated's valuation using real-world financial data, with complete flexibility to modify all essential parameters for improved projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,162.8 | 6,205.7 | 7,574.4 | 8,930.7 | 9,869.2 | 10,748.3 | 11,705.8 | 12,748.5 | 13,884.1 | 15,120.9 |
| Revenue Growth, % | 0 | 49.07 | 22.06 | 17.91 | 10.51 | 8.91 | 8.91 | 8.91 | 8.91 | 8.91 |
| EBITDA | 1,560.4 | 3,284.5 | 2,917.5 | 4,435.5 | 4,605.2 | 4,842.3 | 5,273.6 | 5,743.4 | 6,255.0 | 6,812.1 |
| EBITDA, % | 37.48 | 52.93 | 38.52 | 49.67 | 46.66 | 45.05 | 45.05 | 45.05 | 45.05 | 45.05 |
| Depreciation | 106.9 | 109.5 | 125.6 | 148.3 | 181.3 | 204.0 | 222.2 | 242.0 | 263.5 | 287.0 |
| Depreciation, % | 2.57 | 1.76 | 1.66 | 1.66 | 1.84 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 |
| EBIT | 1,453.4 | 3,174.9 | 2,791.9 | 4,287.2 | 4,423.9 | 4,638.3 | 5,051.4 | 5,501.4 | 5,991.5 | 6,525.2 |
| EBIT, % | 34.91 | 51.16 | 36.86 | 48.01 | 44.83 | 43.15 | 43.15 | 43.15 | 43.15 | 43.15 |
| Total Cash | 3,808.3 | 6,658.9 | 7,524.9 | 10,778.5 | 11,218.3 | 10,551.2 | 11,491.1 | 12,514.7 | 13,629.5 | 14,843.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 633.5 | 885.4 | 1,136.8 | 1,442.2 | 1,563.4 | 1,644.1 | 1,790.6 | 1,950.1 | 2,123.8 | 2,313.0 |
| Account Receivables, % | 15.22 | 14.27 | 15.01 | 16.15 | 15.84 | 15.3 | 15.3 | 15.3 | 15.3 | 15.3 |
| Inventories | 167.5 | 280.8 | 353.1 | 460.6 | 738.8 | 555.8 | 605.3 | 659.2 | 717.9 | 781.9 |
| Inventories, % | 4.02 | 4.52 | 4.66 | 5.16 | 7.49 | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 |
| Accounts Payable | 87.6 | 155.1 | 195.0 | 303.9 | 364.9 | 307.0 | 334.3 | 364.1 | 396.5 | 431.8 |
| Accounts Payable, % | 2.1 | 2.5 | 2.57 | 3.4 | 3.7 | 2.86 | 2.86 | 2.86 | 2.86 | 2.86 |
| Capital Expenditure | -75.5 | -259.8 | -235.0 | -204.7 | -258.4 | -301.2 | -328.0 | -357.3 | -389.1 | -423.7 |
| Capital Expenditure, % | -1.81 | -4.19 | -3.1 | -2.29 | -2.62 | -2.8 | -2.8 | -2.8 | -2.8 | -2.8 |
| Tax Rate, % | 17.36 | 17.36 | 17.36 | 17.36 | 17.36 | 17.36 | 17.36 | 17.36 | 17.36 | 17.36 |
| EBITAT | 1,226.2 | 2,762.3 | 2,394.9 | 3,365.0 | 3,656.0 | 3,880.2 | 4,225.8 | 4,602.2 | 5,012.2 | 5,458.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 544.2 | 2,314.4 | 2,001.5 | 3,004.6 | 3,240.5 | 3,827.3 | 3,951.3 | 4,303.3 | 4,686.6 | 5,104.1 |
| WACC, % | 6.3 | 6.3 | 6.3 | 6.29 | 6.3 | 6.3 | 6.3 | 6.3 | 6.3 | 6.3 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 18,112.8 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 5,257 | |||||||||
| Terminal Value | 159,477 | |||||||||
| Present Terminal Value | 117,518 | |||||||||
| Enterprise Value | 135,631 | |||||||||
| Net Debt | -9,561 | |||||||||
| Equity Value | 145,191 | |||||||||
| Diluted Shares Outstanding, MM | 261 | |||||||||
| Equity Value Per Share | 557.36 |
What You Will Get
- Editable Forecast Inputs: Easily adjust assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Vertex Pharmaceuticals’ (VRTX) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that tailors to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and saving time.
Key Features
- Real-Life VRTX Data: Pre-filled with Vertex Pharmaceuticals' historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- 1. Access the Template: Download and open the Excel file featuring Vertex Pharmaceuticals Incorporated’s (VRTX) preloaded data.
- 2. Modify Assumptions: Adjust critical inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Immediately: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation results.
- 5. Present with Assurance: Deliver professional valuation insights to back your strategic decisions.
Why Choose Vertex Pharmaceuticals (VRTX)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Track Record: A history of successful drug development and market introduction.
- Commitment to Research: Significant investment in R&D to drive future breakthroughs.
- Patient-Centric Approach: Focused on improving patient outcomes and quality of life.
- Recognized Leadership: Esteemed by industry experts for excellence and reliability.
Who Should Use Vertex Pharmaceuticals Incorporated (VRTX)?
- Investors: Make informed investment choices with insights into the biotech sector.
- Healthcare Analysts: Leverage comprehensive data for in-depth analysis of pharmaceutical trends.
- Consultants: Tailor research findings for client discussions or strategic recommendations.
- Biotech Enthusiasts: Expand your knowledge of drug development and market dynamics with real case studies.
- Educators and Students: Utilize it as a resource for understanding the intricacies of the pharmaceutical industry.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Vertex Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Vertex Pharmaceuticals (VRTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.